Antibody Drug Conjugates
Design, Discovery, and Development
Series: AAPS Advances in the Pharmaceutical Sciences Series; 52;
- Publisher's listprice EUR 139.09
-
57 687 Ft (54 940 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 12% (cc. 6 922 Ft off)
- Discounted price 50 765 Ft (48 347 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
57 687 Ft
Availability
Not yet published.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Springer Nature Switzerland
- Date of Publication 3 January 2026
- Number of Volumes 1 pieces, Book
- ISBN 9783031893186
- Binding Hardback
- No. of pages232 pages
- Size 235x155 mm
- Language English
- Illustrations VIII, 232 p. 35 illus., 24 illus. in color. Illustrations, black & white 700
Categories
Long description:
"
This volume provides a comprehensive recapitulation of structure-activity relationship (SAR) from a mechanism of action point of view for this unique therapeutic modality, in a largely disease agnostic manner. From a disease biology and pharmacology perspective, the cellular target and drug-conjugate selection, considerations on liker -chemistry and -antibody ratio, and formulation science and technology, to get from bench to bedside (i.e. from a laboratory to the systemic circulation in a patient). The book also provides an understanding around target binding and drug/""payload"" release mechanisms. Furthermore, pharmacokinetic and safety pharmacological aspects from a regulatory and clinical perspective are discussed, along with current chemistry, manufacturing, controls guidance and emerging novel delivery devices or technologies.
The key differentiation in Antibody Drug Conjugates is the clinical and development discussion, that offers pragmatic considerations in medical product development, IP, regulatory considerations, among others. Furthermore, we discuss the topic as a platform, in a disease agnostic manner.
" MoreTable of Contents:
Commercialized ADCs: A Market Snapshot for Exemplification.- Application of ADCs to Therapeutic Areas Outside of Oncology.- Regulatory framework for the manufacturing and marketing of ADCs.- Conjugation Chemistry and Chemical Design for the Discovery and Development of Antibody Drug Conjugates.- Clinical Pharmacology Considerations in Antibody-Drug Conjugates Development.- Bioanalytical Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugates.- Toxicology Considerations on Antibody-Drug Conjugate Discovery and Development.- Considerations for Antibody Drug Conjugate Design Stability and Formulation.
More
